SCHEMBL6169101

SCHEMBL6169101

Cc1nc2cc(C(=O)NCc3ccccn3)ccc2n1CCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.59
ALDH1A1 P00352 4/20 0.59
GAA P10253 2/20 0.59
HTT P42858 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
GLA P06280 1/20 0.59
NAMPT P43490 1/20 0.57
PPARG P37231 3/20 0.56
RORC P51449 1/20 0.54
PIK3CA P42336 1/20 0.52
MAPT P10636 3/20 0.50
POLB P06746 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
HPGD P15428 2/20 0.50
ALOX15 P16050 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168528 0.92 KDM4E (0.59) KDM4EALDH1A1GAAHTTSMN1; SMN2
SCHEMBL6169929 0.83 PPARG (0.61) KDM4EALDH1A1GLANAMPTPPARG
SCHEMBL6170298 0.82 PPARG (0.58) KDM4EALDH1A1GAAHTTSMN1; SMN2
SCHEMBL6170173 0.80 RORC (0.59) KDM4EALDH1A1GAAPPARGRORC
SCHEMBL19987366 0.80 HSD17B10 (0.59) KDM4EHTTPPARGPOLBMEN1
SCHEMBL6171597 0.79 HDAC3 (0.57) KDM4EGAANAMPTPPARGRORC
SCHEMBL7596545 0.79 NAMPT (0.54) KDM4EALDH1A1NAMPTRORCPIK3CA
SCHEMBL6170064 0.78 ALDH1A1 (0.53) KDM4EALDH1A1SMN1; SMN2NAMPTPPARG
SCHEMBL6170887 0.77 LMNA (0.58) KDM4EALDH1A1HTTSMN1; SMN2GLA
SCHEMBL6168481 0.76 KDM4E (0.58) KDM4EALDH1A1HTTNAMPTPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives OSI PHARMACEUTICALS, INC. 2002-06-27 US disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6348032-B1 POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. CELL PATHWAYS, INC. 2002-02-19 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives MKI67, CCNI, TMBIM6 KDM4E 2132/4885ALDH1A1 487/4885GAA 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.